Phase 2 Alzheimer's Disease Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged between 55 and 85 years (inclusive) at the time of signing the consent form.
- People who have been diagnosed with either mild cognitive impairment due to Alzheimer's disease, or mild Alzheimer's disease dementia (specific stages as defined by NIA-AA guidelines).
- People who have scored between 0.5 and 1.0 on a standard memory and thinking assessment called the Clinical Dementia Rating scale, with a memory-specific score of at least 0.5 at the screening visit.
- People who have a study partner who is over 18 years old, has known the participant for at least one year, spends at least 8 hours per week with the participant, and is willing to provide written consent to take part separately.
- People who have a brain scan (called an amyloid PET scan) showing the presence of amyloid plaques, which are a key feature of Alzheimer's disease.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a history of significant brain or neurological conditions, including (but not limited to) frontotemporal dementia, Lewy body dementia, Huntington's disease, serious brain infection, Parkinson's disease, multiple concussions, multiple sclerosis, or epilepsy or repeated seizures (childhood febrile seizures are an exception).
- People whose brain scans show more than 4 very small bleeds (under 10mm) or a condition called superficial siderosis (iron deposits on the brain surface).
- People who carry two copies of a specific gene variant called APOE4 (sometimes written as APOE4/4).
- People who are currently receiving, or have previously received, any anti-amyloid immunotherapy treatment (such as aducanumab, lecanemab, or donanemab) or a type of therapy that targets a protein called TREM-2.
- People who are currently taking blood-thinning (anticoagulant) medications.
- People who have had a cancer diagnosis in the 3 years before the screening visit, with some exceptions including certain skin cancers, early-stage prostate cancer, fully removed kidney cancers, and successfully treated cervical carcinoma in situ (confirm with trial site for full details).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 800-633-1610
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Part A and optional dose 2 cohort: change from baseline to Week 48 in plasma p-tau217; Part B: Number of participants with treatment-emergent adverse events (TEAE), including ARIA-E and ARIA-H by brain MRI, laboratory assessments, vital sign measurements, ECGs and the C-SSRS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.